Three insiders at AgomAb Therapeutics NV reported open-market purchases of $AGMB shares between October 5 and October 8, 2026. Their Form 4 filings showed eight separate transactions with a combined value of $311,170, and every transaction was marked as an open-market buy. The purchases took place across three trading dates: October 5, October 6, and October 8.
The buying group included the company's CEO, CFO, and a director. Across the cluster, the three filers acquired 36,000 shares at per-share prices ranging from $8.48 to $8.90. All three filers were individuals rather than funds or entities, and each Form 4 carried the open-market purchase designation. The highest per-share price in the group was $8.90, reported on the October 8 director purchase.
CEO Tim Jasper Knotnerus reported two purchases. He bought 6,000 shares at $8.48 per share, or $50,880, on October 5, and 5,000 shares at $8.70 per share, or $43,500, on October 6. The filings listed 11,000 shares acquired across the two transactions and 21,823 shares owned after the second purchase. His two-trade dollar total was $94,380.
Director David R Epstein reported the largest dollar total in the cluster. He bought 5,000 shares at $8.57 per share, or $42,850, on October 5; 5,000 shares at $8.70 per share, or $43,500, on October 6; and 5,000 shares at $8.90 per share, or $44,500, on October 8. The three transactions totaled $130,850 and left him with 15,000 shares owned after the final filing. His purchases covered all three trading dates represented in the cluster.
CFO Pierre Thadee Victor Kemula reported three purchases on October 6: 3,000 shares at $8.67 per share ($26,010), 5,000 shares at $8.57 per share ($42,850), and 2,000 shares at $8.54 per share ($17,080). His filings showed 10,000 shares acquired and 10,000 shares owned after the purchases, for a total of $85,940.
In total:
- Tim Jasper Knotnerus, CEO: 11,000 shares, $94,380
- David R Epstein, Director: 15,000 shares, $130,850
- Pierre Thadee Victor Kemula, CFO: 10,000 shares, $85,940
The October 5 transactions were reported to the SEC on October 7, two days after the trade. The October 6 transactions were filed on October 7, and the October 8 transaction was filed on October 9. The cluster consisted of eight buys by three individuals over four calendar days, with no other transaction types reported. Before October 5, no $AGMB Form 4 transactions were present in the company's insider-filing history. The congressional STOCK Act disclosure record showed no $AGMB trades. AgomAb Therapeutics NV is a pharmaceuticals company with a market capitalization of about $435 million.